Indication
as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase positive (ALK+) advanced non-small cell lung cancer (NSCLC) previously treated with crizotinib

Medicine details

Medicine name:
brigatinib (Alunbrig)
SMC ID:
SMC2147
Pharmaceutical company
Takeda UK Ltd
BNF chapter
Submission type
Full
Status
Advice due date:
10 June 2019
SMC meeting date:
07 May 2019
Patient group submission deadline:
04 March 2019